Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.73 |
| ▸ | NPY4R | P50391 | 8/20 | 0.73 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.73 |
| ▸ | NPY1R | P25929 | 6/20 | 0.73 |
| ▸ | TFPI | P10646 | 5/20 | 0.67 |
| ▸ | CALCR | P30988 | 5/20 | 0.67 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496391 | 0.97 | NPY2R (0.72) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL13248707 | 0.96 | NPY2R (0.80) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29496288 | 0.95 | NPY2R (0.74) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29783624 | 0.93 | CALCR (0.73) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29783636 | 0.93 | CALCR (0.73) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29783640 | 0.93 | CALCR (0.73) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29783629 | 0.93 | CALCR (0.73) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29783631 | 0.93 | CALCR (0.73) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29783626 | 0.93 | CALCR (0.73) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29526997 | 0.93 | NPY2R (0.72) | NPY2RNPY4RNPY5RNPY1RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112888705-B | Protein tyrosine-tyrosine analogues and methods of use thereof | 伊莱利利公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119156221-A | Improved oral pharmaceutical formulations of therapeutic peptides and proteins | 西普鲁梅有限公司 | 2024-12-17 | — | — | CN | claimed |
| WO-2024212843-A1 | PEPTIDE TYROSINE-TYROSINE ANALOG AND USE THEREOF | 联邦生物科技(珠海横琴)有限公司 | 2024-10-17 | — | — | WO | claimed |
| CN-114075265-A | Polypeptide tyrosine analogue and sustained-release preparation containing same | 丽珠医药集团股份有限公司 | 2022-02-22 | — | — | CN | claimed |
| CN-122097550-A | GLP-1 and PYY3-36Polypeptide analogue composition and preparation method and application thereof | — | 2026-05-29 | — | — | CN | disclosed |
| EP-4743083-A1 | METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZAR | Pleiogenix Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3257523-B1 | USE OF POLYPEPTIDE COMPLEX AS POLYPEPTIDE OR PROTEIN DRUG CARRIER, METHOD, AND FUSION PROTEIN COMPLEX THEREOF | TIANJIN INST IND BIOTECHNOLOGY CAS (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12617830-B2 | Analogues of PYY | IP2IPO INNOVATIONS LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| CN-121895435-A | PYY analogue and application thereof in treatment of diseases | 孙涛 | 2026-04-21 | — | — | CN | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| CN-107001485-B | Protein heterodimers and uses thereof | 苏州丁孚靶点生物技术有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| WO-2022040058-A1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022040070-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220056017-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | US | disclosed |
| CN-114075265-A | Polypeptide tyrosine analogue and sustained-release preparation containing same | 丽珠医药集团股份有限公司 | 2022-02-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | NPY2R 111/4885NPY4R 74/4885NPY5R 247/4885 |
| US-12617830-B2 | Analogues of PYY | GLP1R, INSR, GIPR | NPY2R 31/4885NPY4R 22/4885NPY5R 81/4885 |
| US-20220056017-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | NPY2R 7/4885NPY4R 14/4885NPY5R 12/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | NPY2R 791/4885NPY4R 331/4885NPY5R 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.